Overview

An Open-Label Study to Determine Safety , Tolerability, and Efficacy of Oral Lacosamide in Children With Epilepsy

Status:
Completed
Trial end date:
2021-05-18
Target enrollment:
Participant gender:
Summary
SP848 is an open-label study to evaluate long-term safety, tolerability, and efficacy in children with epilepsy treated with Lacosamide (LCM) oral solution (syrup) or LCM tablets as adjunctive therapy.
Phase:
Phase 2
Details
Lead Sponsor:
UCB Pharma
Treatments:
Lacosamide